Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Ocugen, Inc. announced that it is diversifying its innovative pipeline by introducing a Phase III, cell therapy platform technology called NeoCart®, autologous chondrocyte-derived neocartilage.